First Line Gefitinib by FDG-PET Metabolic Response
Status:
Unknown status
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
When considering 1st line gefitinib treatment for NSCLC, the investigators need epidermal
growth factor receptor (EGFR) mutational status of the tumor. But most patients do not give
us such information at the time of diagnosis, because it requires tumor tissue and some time
period for EGFR examination. So, investigators develop a protocol of 1st line gefitinib
treatment for NSCLC according to FDG-PET response. If a patient shows 20% or more decrease of
peak standard uptake value (SUV) after 1 week's gefitinib treatment, he or she will be
continued the treatment. If a patient shows less than 20% decrease of SUV, he or she will be
switched to other chemotherapy.